Medical News Today -
23 Oct 2013 12:00
Researchers have discovered a biomarker that could help predict whether patients with melanoma harboring mutations in the BRAF gene are likely to respond to BRAF-targeted treatment. The discovery could help speed up treatment decisions, say the researchers. They presented their findings at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23 in Boston, MA. About 50% of melanomas have mutations in the BRAF gene, and there are two federa...
Share this Article